Melder Katie L, Geltzeiler Mathew
Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, OR 97239, USA.
Cancers (Basel). 2023 Jul 26;15(15):3798. doi: 10.3390/cancers15153798.
Sinonasal squamous cell carcinoma (SNSCC) and sinonasal undifferentiated carcinoma (SNUC) are two of the most common, high-grade malignancies of the sinonasal cavity. The standard of care for resectable lesions per the National Comprehensive Cancer Network (NCCN) guidelines includes surgical resection with negative margins plus adjuvant radiation therapy. However, surgery for locally advanced disease with both orbital and intracranial involvement is associated with significant morbidity and poor overall survival. Over the last decade, induction chemotherapy (IC) has emerged as part of a multimodal treatment strategy to optimize locoregional disease control and minimize substantial surgical morbidity such as orbital exenteration without compromising rates of overall survival. The response to IC both guides additional therapy and helps prognosticate a patient's disease. This narrative review examines the data surrounding the management of patients with SNSCC and SNUC. The pros and cons of upfront surgical management plus adjuvant therapy will be explored, and the case for IC will be presented. The IC-specific regimens and treatment paradigms for SNSCC and SNUC will each be explored in detail. Organ preservation, treatment morbidity, and survival data will be presented, and evidence-based recommendations will be presented for the management of these patients.
鼻窦鳞状细胞癌(SNSCC)和鼻窦未分化癌(SNUC)是鼻窦腔最常见的两种高级别恶性肿瘤。根据美国国立综合癌症网络(NCCN)指南,可切除病变的标准治疗方案包括手术切除切缘阴性加辅助放疗。然而,对于伴有眼眶和颅内受累的局部晚期疾病进行手术,会带来显著的发病率且总体生存率较差。在过去十年中,诱导化疗(IC)已成为多模式治疗策略的一部分,以优化局部区域疾病控制,并在不影响总体生存率的情况下,将诸如眶内容摘除术等严重手术发病率降至最低。对诱导化疗的反应既指导进一步治疗,也有助于预测患者的疾病情况。本叙述性综述探讨了围绕SNSCC和SNUC患者管理的数据。将探讨 upfront 手术管理加辅助治疗的利弊,并阐述诱导化疗的理由。将分别详细探讨SNSCC和SNUC的诱导化疗特定方案和治疗模式。将呈现器官保留、治疗发病率和生存数据,并为这些患者的管理提出基于证据的建议。